What does Cysteamine do?#
Cysteamine is a brightening ingredient that helps visibly reduce the appearance of dark spots and stubborn areas of uneven tone.
Benefits
- Helps reduce the visible appearance of stubborn dark spots
- Backed by consistent published research on the look of dark spots and age spots
- Supports a more even, uniform-looking complexion with consistent use
How it works
Cysteamine is a relatively recent arrival in skincare — it took a long time to make it stable enough to formulate with — and it is valued for helping visibly reduce the appearance of stubborn dark spots. It suits a steady evening habit: the change builds over weeks rather than days, and most people are looking at around the second month before it is at its best.
What to expect
When you first start, you may notice some warmth or tingling, a little dryness, and the look of mild redness — this usually eases within about a week and keeps settling from there. Any warmth on application tends to fade within about half an hour. Keeping a moisturizer in your routine helps through the first couple of weeks.
How to use Cysteamine#
Before you start
Skip it on the day of a facial, laser, microneedling or injectables, and for the week after.
Best time
Every study that specified a time used it at night.
Where to apply
Keep it away from the eye area.
How to apply
Apply to dry skin rather than freshly washed skin — if you have just cleansed, give it about an hour first. This is the single easiest thing to get right, and it makes it more comfortable.
How long
Follow the timing on the pack. Some cysteamine products are meant to be rinsed off after a short time rather than left on, and the two kinds are used quite differently. Leaving it on longer does not give a better result — the research points the other way.
Sun
Wear sunscreen daily. Cysteamine isn't one of the actives we flag for extra sun care - and sun exposure is what drives the look of the marks you're working on, so daily protection earns its place either way.
Alongside others
Moisturize straight afterwards. It is part of how this ingredient is meant to be used, not an optional extra.
What to expect
It has a distinctive sulfur-like scent. That is normal for this ingredient and not a sign anything is wrong.
Expect some warmth, tingling or the look of mild redness in the first week, easing from there. Warmth on application tends to fade within about half an hour.
Give it time — the change builds over weeks, and around the second month is when it tends to be at its best.
If it doesn't suit
Stop using it if the skin around a dark patch starts to look lighter than the rest, or if irritation persists.
Mild warmth, stinging or the look of redness may occur when you first start. Keep it away from the eye area. Not recommended during pregnancy or breastfeeding, as it has not been studied in either. Discontinue use if persistent irritation occurs, or if the skin around a dark patch starts to look lighter than the rest.
The form you will see it in
Cysteamine corrector
- Where it goes
- Before moisturizer
Using Cysteamine with other ingredients
Pairs well with Cysteamine
Niacinamide
Works well togetherNiacinamide supports a resilient, even-looking complexion, complementing cysteamine's brightening benefits.
Tranexamic acid
Works well togetherComplementary brightening support — together they help promote a more even, uniform-looking complexion from two different angles.
Ectoin
Works well togetherEctoin supports a comfortable, calm-looking complexion, which sits well alongside cysteamine.
What not to use with Cysteamine
Vitamin C
Never the same eveningVitamin C and cysteamine are more comfortable at different times of day than layered together.
Exfoliants
Different timesThese two are better applied on separate evenings rather than layered together.
Glycolic Acid (AHA) · Lactic Acid (AHA) · LHA · Mandelic Acid (AHA) · Salicylic Acid (BHA)
Eye-area retinol
Different timesBetter applied on separate evenings rather than layered around the eyes.
Retinoids
Different timesThese two are better applied on separate evenings rather than layered together.
Who should avoid Cysteamine?#
Six situations change whether Cysteamine suits your skin right now. Each one is either a reason to skip it, a reason to go slowly, or nothing to watch for.
- Maternity & Nursing
- Skip it
- Fragile or Sensitive
- Skip it
- Recent Facial or Laser
- Skip it
- Prone to Redness
- Skip it
- Dry or Itchy Patches
- Skip it
- Recent Shave or Wax
- Go slowly
Recent Shave or Wax — Avoid for 24 hours after waxing, threading, or dermaplaning.
Cosmetic strength limits for Cysteamine where you live#
| Region | Most a cosmetic may contain | |
|---|---|---|
| No explicit cap | ||
The FDA restricts a short list of ingredients and sets no general strength ceiling on the rest. A figure marked "guidance, not law" is the Cosmetic Ingredient Review panel's recommendation. 21 CFR part 700, subpart B — Requirements for Specific Cosmetic Products (FDA) | ||
| No explicit cap | ||
One list does the work — Health Canada's Hotlist of prohibited and restricted cosmetic ingredients. | ||
| No explicit cap | ||
The Cosmetics Regulation's annexes, consolidated to 1 May 2026. A figure marked "guidance, not law" comes from the EU's cosmetic safety committee rather than from the annexes. | ||
| No explicit cap | ||
Great Britain kept the annexes as its own law and updates them only when it chooses; Northern Ireland follows the live EU Regulation, which is why some rows read differently for each. Regulation (EC) No 1223/2009 as it applies in Great Britain · Regulation (EC) No 1223/2009, Annexes II–VI | ||
| No explicit cap | ||
India writes its own standard, aligned to the European rules as they stood in 2012. Mandatory since 9 February 2026. IS 4707 (Part 2):2025 — restricted and prohibited cosmetic ingredients · IS 4707 (Part 3):2025 — preservatives · Cosmetics Rules, 2020, Ninth Schedule | ||
| No explicit cap | ||
ANVISA rewrote its restricted list in June 2026, and a companion act amended the prohibited list at the same time. RDC 1.029/2026 — restricted ingredients · RDC 529/2021 — prohibited ingredients, as amended by RDC 1.030/2026 · RDC 528/2021 — preservatives | ||
| Not permitted in skincare (rinse-off hair products only) | ||
Japan's cosmetics standard keeps drug ingredients out of cosmetics, so most of its figures sit in the ministry's list of the ones a cosmetic may still contain. Cosmetics Standards (化粧品基準), Ministry of Health, Labour and Welfare · Cosmetics Standards — the ministry's own English translation · Drug ingredients permitted in cosmetics — 2007 notification | ||
| No explicit cap | ||
One MFDS regulation carries both the prohibited list and the restricted list, in force 18 March 2026. Sunscreens and a few other categories are cleared product by product instead. Regulation on Safety Standards for Cosmetics (MFDS Notification 2026-19) · Regulation on the Review of Functional Cosmetics (MFDS Notification 2025-88) | ||
| No explicit cap | ||
Kenya's standard applies the EU annexes as they stand rather than copying them, so its ingredient limits are the EU's — including the 2024 additions. A figure marked "guidance, not law" sits outside the annexes and does not carry over. KS EAS 377-1, -2 and -3:2022 — cosmetics safety requirements, published by KEBS · Regulation (EC) No 1223/2009, Annexes II–VI | ||
| No explicit cap | ||
Namibia sets no ingredient limits at all. Its cosmetic rule is a single line requiring a product to be free of any harmful ingredient. Foodstuffs, Cosmetics and Disinfectants Ordinance 18 of 1979, and the regulations under it | ||
| No explicit cap | ||
Ukraine's own transposition of the EU annexes, as they stood before the 2024 additions, fully in force since 3 August 2026. A further revision is due on 1 February 2027. Technical Regulation on cosmetic products — Cabinet Resolution No. 65 of 20 January 2021 | ||
| No explicit cap | ||
Georgia has no cosmetics rulebook — its register of technical regulations carries no cosmetics entry — so only the general product-safety duty applies. | ||
| 1% (unscheduled); 6% (with Caution labeling) | ||
Australia writes no cosmetic ingredient list. A figure here is the point at which a substance becomes a medicine or a scheduled substance carrying Caution labeling, so its numbers sit well above other markets'. Poisons Standard — June 2026 · Therapeutic Goods (Excluded Goods) Determination 2018 | ||
| No explicit cap | ||
The Gulf standard points at the EU annexes as amended, so its ingredient limits are the EU's. A figure marked "guidance, not law" sits outside the annexes and does not carry over. GSO 1943:2024 — Cosmetic products: safety requirements (Gulf technical regulation) · Regulation (EC) No 1223/2009, Annexes II–VI | ||
| No explicit cap | ||
The Gulf standard points at the EU annexes as amended, so its ingredient limits are the EU's. A figure marked "guidance, not law" sits outside the annexes and does not carry over. GSO 1943:2024 — Cosmetic products: safety requirements (Gulf technical regulation) · Regulation (EC) No 1223/2009, Annexes II–VI | ||
| No explicit cap | ||
Hong Kong writes no cosmetics rulebook. Its Poisons List (Cap. 138A, Schedule 10) decides which substances may be sold only as medicines, and general safety is judged case by case against whichever overseas standard the enforcer considers reasonable. Pharmacy and Poisons Regulations (Cap. 138A), Schedule 10 — the poisons list · Pharmacy and Poisons Board — Guidance Notes on classifying pharmaceutical products, April 2026 | ||
| No explicit cap | ||
Singapore writes the ASEAN annexes into its own schedule, and its regulator tells companies to check the current ASEAN release as well — which is why a figure here can read "guidance, not law". Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007, Third Schedule · ASEAN Cosmetic Directive annexes — release 2026-1, 22 June 2026 | ||
| No explicit cap | ||
Brunei carries the 2007 ASEAN annexes in its own schedule and has not updated them since, so it reads differently from Singapore on several ingredients. Medicines (Cosmetic Products) Regulations (Cap. 285 Rg 1), Schedule 1 — revised edition 2024 | ||
| No explicit cap | ||
Jordan's cosmetic rules defer to "the approved references" and name none of them, so there is no Jordanian figure to read. The only number in the instrument governs the ingredient list on the pack. JFDA instructions on cosmetics and pharmaceutical cosmetics, 2026 | ||
| No explicit cap | ||
Trinidad and Tobago has had the power to set cosmetic standards since 1960 and has never used it. The regulations made under the Act cover food and drugs, with no cosmetics part; what binds is the Act's general rule against selling a cosmetic that may injure the user. Food and Drugs Act, Chap. 30:01 · Food and Drugs Regulations | ||
Where a figure appears, that is the maximum strength allowed or advised for cysteamine in that market — some are set in cosmetics regulation, others are the ceiling a cosmetic safety panel recommends. Where no figure appears, the market either sets no cosmetic maximum or handles this ingredient outside its cosmetic rules. These are limits, not targets — the right strength for a formula is the formulator's decision. Some products containing this ingredient at higher strengths are prescription medicines, not cosmetics.
Open a market to see the rulebook its figure comes from. Those notes describe each market's own rules as we read them, current to August 24, 2026; the linked documents are the authority, and nothing here is legal advice.
Sample products with Cysteamine#
A few well-known products, not a full list — product names are each brand's own. We don't sell them — the shop prices them in US dollars and ships from Hong Kong, so delivery and duties come on top. It may not ship everywhere.
We may earn a small commission when you buy through these links.
Serums · 3
Already have one? Check how it fits your skin with Pick.
Common questions about Cysteamine#
What is Cysteamine?
- A brightening ingredient used on stubborn dark spots and age spots, to help the skin look more even in tone.
What else is Cysteamine called?
- On a label you may see Cysteamine hydrochloride.
When should you apply Cysteamine?
- Evening. Every study that specified a time used it at night.
How often can you use Cysteamine?
- Daily, all over the face, not the eye area.
Where do you apply Cysteamine?
- All over the face, not the eye area. Keep it off your lips too.
Can you use Cysteamine around the eyes?
- No. Cysteamine goes all over the face, not the eye area.
Does Cysteamine make skin more sensitive to the sun?
- No. Cysteamine is not flagged as increasing sun sensitivity.
What should you not use with Cysteamine?
- Not on the same evening as Vitamin C. Space it apart from Exfoliants, Eye-area retinol and Retinoids.
Who should avoid Cysteamine?
- Skip it if any of these apply: Maternity & Nursing, Fragile or Sensitive, Recent Facial or Laser, Prone to Redness and Dry or Itchy Patches. Go slowly with Recent Shave or Wax.
Is there a cosmetic limit for Cysteamine?
- No. No cosmetic regulator in the United States, Canada, the European Union or Great Britain sets a maximum strength for it. That is a limit on the rules, not a signal to use more. Some products containing this ingredient at higher strengths are prescription medicines, not cosmetics.
Related ingredients#
How we check this#
Everything on this page traces to the sources listed below — regulators' own publications and published studies. Where the evidence does not answer a question, it is left unanswered.
Some sources below are the official product information for prescription medicines — some contain this ingredient at higher strengths, others are cited for how they interact with it. We use them for their safety and handling detail only. A cosmetic product is not one of those medicines and is not intended to treat any condition.
Our review is AI-assisted and is not a named expert's opinion. Last reviewed August 5, 2026.
Think something here is out of date or wrong? Email us at wiki@skinintelligence.ai with your reasoning and where you read it. We read what people send, and we update the page when the sources support it.
Regulators and official bodies · 11
- S1EMA. Cystagon (mercaptamine bitartrate) — Summary of Product Characteristics, §§ 4.1–4.9.
- S2EMA. Cystadrops (mercaptamine hydrochloride) — Summary of Product Characteristics, §§ 4.3–4.8.
- S3FDA. CYSTARAN (cysteamine ophthalmic solution) 0.44% label, 2012 (accessdata NDA 200740).
- S4FDA / DailyMed. CYSTAGON (cysteamine bitartrate) capsules label.
- S5Health Canada. Prescription Drug List — list related to drugs for human use (FDA s. 29.1). Entry "Cysteamine (Mercaptamine) or its salts", Qualifier column blank, effective 2017-08-04.
- S6Health Canada. Cosmetic Ingredient Hotlist — prohibited and restricted ingredients. Cysteamine absent (verified null).
- S7FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) — FD&C Act §§ 201(i), 201(g)(1); melanin-production claims named as drug claims.
- S8eCFR, 21 CFR Part 700 Subpart B, §§ 700.11–700.35. Cysteamine absent (verified null).
- S9Regulation (EC) No 1223/2009 on cosmetic products, consolidated text 01.05.2026 (EUR-Lex, CELEX 02009R1223-20260501), Annexes II–VI. Cysteamine absent (verified null against hydroquinone, thioglycolic acid, kojic acid, arbutin as controls).
- S10Regulation (EC) No 1223/2009 as retained in UK law (legislation.gov.uk/eur/2009/1223), Annex II and Annex III, adopted and amended texts. Cysteamine absent (verified null against mercury, thioglycolic acid, kojic acid as controls).
- S11Commission Implementing Decision (EU) 2019/701 establishing a glossary of common ingredient names for use in the labelling of cosmetic products (Art. 33 of Reg. 1223/2009). CYSTEAMINE and CYSTEAMINE HCL both listed.
Studies and references · 33
- S12Mansouri P, Farshi S, Hashemi Z, Kasraee B. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol 2015;173:209–17. PMID 25251767.
- S13Farshi S, Mansouri P, Kasraee B. Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method. PMID 28678558.
- S14Karrabi M, David J, Sahebkar M. Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma. Skin Res Technol 2021;27:24–31. PMID 32585079.
- S15Karrabi M, Mansournia MA, Sharestanaki E, Abdollahnejad Y, Sahebkar M. Clinical evaluation of efficacy and tolerability of cysteamine 5% cream in comparison with tranexamic acid mesotherapy in subjects with melasma. Arch Dermatol Res 2021. PMID 32879998.
- S16Nguyen J, Remyn L, Chung IY, Honigman A, Gourani-Tehrani S, Wutami I, Wong C, Paul E, Rodrigues M. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: a randomised, double-blinded trial. Australas J Dermatol 2021;62:e41–e46. PMID 32981068.
- S17Sepaskhah M, Karimi F, Bagheri Z, Kasraee B. Comparison of the efficacy of cysteamine 5% cream and hydroquinone 4%/ascorbic acid 3% combination cream in the treatment of epidermal melasma. J Cosmet Dermatol 2022;21:2871–8. PMID 35510765.
- S18Ahmadi K, Miri A, Bizaval Z, Sepaskhah M, Ranjbar S, Bagheri Z. Assessing the effectiveness of stabilized cysteamine 5% cream compared to hydroquinone 4%/ascorbic acid 3% combination cream in treating acne-induced post-inflammatory hyperpigmentation. J Clin Aesthet Dermatol 2024. PMID 38638185.
- S19Crocco EI, Torloni L, Fernandes PB, de Campos MEBB, Gonzaga M, Silva FC. Combination of 5% cysteamine and 4% nicotinamide in melasma: efficacy, tolerability, and safety. J Cosmet Dermatol 2024;23:1703–12. PMID 38327114.
- S20Khatri KA, Abdullah NA, Chia S, Ng E, Thibroni N. Efficacy, safety, satisfaction, adherence to treatment with nano-formulated cysteamine tranexamic acid cream to treat melasma. J Drugs Dermatol 2024;23:529–37. PMID 38954613.
- S21Wu BQ, Wang YJ, Chang CC, Juang TY, Huang YH, Hsu YC. Clinical efficacy of cysteamine application for melasma: a meta-analysis. J Clin Med 2024. PMID 39685940.
- S22Mawu FO, Christopher PM. Efficacy and safety of cysteamine 5% cream for the management of melasma: a systematic review and meta-analysis of randomized controlled trials. Arch Dermatol Res 2024;317:117. PMID 39673630.
- S23Ahramiyanpour N, Saki N, Akbari Z, Shamsi-Meymandi S, Amiri R, Heiran A. Efficacy of topical cysteamine hydrochloride in treating melasma: a systematic review. J Cosmet Dermatol 2021;20:3593–602. PMID 34591360.
- S24Desai S, Hartman C, Grimes P, Shah S. Topical stabilized cysteamine as a new treatment for hyperpigmentation disorders: melasma, post-inflammatory hyperpigmentation, and lentigines. J Drugs Dermatol 2021;20:1276–9. PMID 34898155.
- S25Saki N, Modabber V, Kasraei H, Kasraee B. Successful treatment of solar lentigines by topical application of stabilized cysteamine: a vehicle-controlled, double-blind randomized study. Health Sci Rep 2024. PMID 38410492.
- S26Tsai YW, Lin JH, Lai YJ, Liu TL, Ng CY. Efficacy and safety of combination therapy of microneedling radiofrequency, in-office and home-based topical cysteamine in refractory melasma: a split-face, vehicle-control, randomized control trial. J Cosmet Dermatol 2024. PMID 39574411.
- S27Clark-Loeser L, Sfriso R, Dirlewanger L, Kasraee B. A case series with cysteamine–isobionicamide complex: clues for skin-rejuvenating activity. J Cosmet Dermatol 2025. PMID 39817605.
- S28Kusumawardani A, Murasmita A, Rosmarwati E, Norawati Ashadi L, Setiawan SV, Murlistyarini S, Wahyu Fitriyani N. Efficacy of overnight leave-on sandwich therapy with 5% cysteamine and ectoine cream compared to hydroquinone 4% cream for treatment of melasma. Acta Dermatovenerol Alp Pannonica Adriat 2025;34:1–4. PMID 40127492.
- S29Patil R, Dhoot D, Balasubramanian A, Patil S, Barkate H. Comparison of the effectiveness and safety of 5% cysteamine and 2% kojic acid creams in the treatment of melasma in Indian adult females. Cureus 2025. PMID 40296942.
- S30Sarkar R, Sahu A, Mendiratta V. Efficacy and safety of cysteamine in melasma in patients of skin of colour: a brief report. Indian Dermatol Online J 2025. PMID 40125051.
- S31Bjerring P, Draelos ZD, Fabi SG, Goodman GJ, Hau KC, Haus A, et al. International expert consensus on integrated skincare active ingredients for pretreatment and posttreatment use with medical aesthetic procedures to enhance skin benefits. J Cosmet Dermatol 2025. PMID 42087526.
- S32Biaglow JE, Issels RW, Gerweck LE, Varnes ME, Jacobson B, Mitchell JB, Russo A. Factors influencing the oxidation of cysteamine and other thiols. Radiat Res 1984;100:298–312. PMID 6093188.
- S33Atallah C, Charcosset C, Greige-Gerges H. Challenges for cysteamine stabilization, quantification, and biological effects improvement. J Pharm Anal 2020. PMID 33425447.
- S34Atallah C, Viennet C, Robin S, Ibazizen S, Greige-Gerges H, Charcosset C. Effect of cysteamine hydrochloride-loaded liposomes on skin depigmenting and penetration. Eur J Pharm Sci 2022;168:106082. PMID 34822973.
- S35Boo YC. Metabolic basis and clinical evidence for skin lightening effects of thiol compounds. Antioxidants (Basel) 2022;11:503. PMID 35326153.
- S36González-Molina V, Martí-Pineda A, González N. Topical treatments for melasma and their mechanism of action. J Clin Aesthet Dermatol 2022. PMID 35642229.
- S37Mathe N, Balogun M, Yoo J. A case report on the use of topical cysteamine 5% cream in the management of refractory post-inflammatory hyperpigmentation resistant to triple combination cream. J Cosmet Dermatol 2021;20:204–6. PMID 32997864.
- S38Gan C, Rodrigues M. An update on new and existing treatments for the management of melasma. Am J Clin Dermatol 2024;25:717–33. PMID 38896402.
- S39Ghasemiyeh P, Fazlinejad R, Kiafar MR, Rasekh S, Mokhtarzadegan M, Mohammadi-Samani S. Different therapeutic approaches in melasma: advances and limitations. PMID 38628650.
- S40Moolla S, Miller-Monthrope Y. Dermatology: how to manage facial hyperpigmentation in skin of colour. PMID 35720052.
- S41Anwar A, Hidayat R, Tabri F, Djawad K, Zainuddin AA, As'aad S, Utomo T, Wong LW, Wijaya JK. Combination of 5% cysteamine serum and 3% tranexamic acid cream using layering technique for treatment of melasma: a pilot study. J Pak Assoc Dermatol 2024. DOI 10.66344/jpad.34.1.2024.2481. Not PubMed-indexed; DOI-bearing..
- S42Symanzik C, Weinert P, Babić Ž, Hallmann S, Havmose MS, Johansen JD, Kezic S, Macan M, Macan J, Strahwald J, Turk R, van der Molen HF, John SM, Uter W. Skin toxicity of selected hair cosmetic ingredients: a review focusing on hairdressers. Int J Environ Res Public Health 2022;19. PMID 35805241.
- S43COSMILE Europe (Cosmetics Europe). CYSTEAMINE HCL ingredient entry — functions: antioxidant; hair waving or straightening; reducing.
- S44DermNet NZ. Cysteamine cream. Author: Mohamed Mahrous, Medical Writer; Editor in Chief: A/Prof Amanda Oakley.



